In lung cancer cells, EZH2 inhibitors65 and HDAC inhibitors66 have been demonstrated to restore MHC-I in vitro, suggesting these drugs might also increase MHC-I in lung tumors. This evidence concerns the gene HDAC9 and lung carcinoma.